Related references
Note: Only part of the references are listed.Trends of ABC control 2006-2011: A National Survey of Diabetes Health Promotion Institutes in Taiwan
Neng-Chun Yu et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2013)
Clinical Characteristics of the Responders to Dipeptidyl Peptidase-4 Inhibitors in Korean Subjects with Type 2 Diabetes
Tae Jung Oh et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2013)
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Silvio E. Inzucchi et al.
DIABETES CARE (2012)
Effect of initial combination therapy with sitagliptin and metformin on β-cell function in patients with type 2 diabetes
D. Williams-Herman et al.
DIABETES OBESITY & METABOLISM (2012)
The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study
Laurent Azoulay et al.
BMJ-BRITISH MEDICAL JOURNAL (2012)
Efficacy and tolerability of sitagliptin monotherapy in elderly patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial
Nir Barzilai et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Neuroprotective properties of GLP-1: theoretical and practical applications
Jens Juul Holst et al.
CURRENT MEDICAL RESEARCH AND OPINION (2011)
Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone Interim report of a longitudinal cohort study
James D. Lewis et al.
DIABETES CARE (2011)
The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus
C. Reasner et al.
DIABETES OBESITY & METABOLISM (2011)
Effect of Sitagliptin as Add-on Therapy in Elderly Type 2 Diabetes Patients With Inadequate Glycemic Control in Taiwan
Ming-Nan Chien et al.
INTERNATIONAL JOURNAL OF GERONTOLOGY (2011)
Efficacy and safety of monotherapy of sitagliptin compared with metformin in patients with type 2 diabetes
P. Aschner et al.
DIABETES OBESITY & METABOLISM (2010)
Efficacy and safety of sitagliptin monotherapy compared with voglibose in Japanese patients with type 2 diabetes: a randomized, double-blind trial
Y. Iwamoto et al.
DIABETES OBESITY & METABOLISM (2010)
Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2-year study
T. Seck et al.
INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (2010)
Use of silkworms for identification of drug candidates having appropriate pharmacokinetics from plant sources
Yukihiro Asami et al.
BMC Pharmacology & Toxicology (2010)
Incretin Therapies: Effects Beyond Glycemic Control
Sunder Mudaliar et al.
AMERICAN JOURNAL OF MEDICINE (2009)
Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea
Viswanathan Mohan et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2009)
Cardiovascular Outcomes in Trials of Oral Diabetes Medications - A Systematic Review
Elizabeth Selvin et al.
ARCHIVES OF INTERNAL MEDICINE (2008)
Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials
Avraham Karasik et al.
CURRENT MEDICAL RESEARCH AND OPINION (2008)
Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes
Kenji Nonaka et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2008)
Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes
M. Florentin et al.
EXPERT OPINION ON PHARMACOTHERAPY (2008)
Are sulphonylureas all the same? A cohort study on cardiovascular and cancer-retated mortality
M. Monami et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2007)
Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes
Steven E. Nissen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2007)
Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: Focus on sitagliptin
G. A. Herman et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2007)
Sitagliptin: Profile of a novel DPP-4 inhibitor for the treatment of type 2 diabetes
Baptist Gallwitz
DRUGS OF TODAY (2007)
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial
M. A. Nauck et al.
DIABETES OBESITY & METABOLISM (2007)
The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes
Daniel J. Drucker et al.
LANCET (2006)
Epidemic obesity and type 2 diabetes in Asia
Kun-Ho Yoon et al.
LANCET (2006)
Dose-response relation between sulfonylurea drugs and mortality in type 2 diabetes mellitus: a population-based cohort study
SH Simpson et al.
CANADIAN MEDICAL ASSOCIATION JOURNAL (2006)
Oral antihyperglycemic therapy for type 2 diabetes - Scientific review
SE Inzucchi
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2002)
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study
IM Stratton et al.
BMJ-BRITISH MEDICAL JOURNAL (2000)
Share Paper
